TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03486782

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IFG stimulation
Description: stimulating inferior frontal cortex with transcranial direct current stimulation for 30 minutes

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IFG stimulation
Description: stimulating inferior frontal cortex with transcranial direct current stimulation for 30 minutes

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IFG stimulation
Description: stimulating inferior frontal cortex with transcranial direct current stimulation for 30 minutes

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DLPFC stimulation
Description: stimulating dorsolateral prefrontal cortex with transcranial direct current stimulation for 30 minutes

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: aphasia therapy
Description: aphasia therapy for 30 minutes during transcranial direct current stimulation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: aphasia therapy
Description: aphasia therapy for 30 minutes during transcranial direct current stimulation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: aphasia therapy
Description: aphasia therapy for 30 minutes during transcranial direct current stimulation
Study: NCT00808392

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Haemophilus influenzae type b vaccine
Description: 3 doses one month apart of Monovalent conjugated vaccine against Haemophilus influenzae type b vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Commercial Haemophilus influenzae type b vaccine
Description: 3 doses one month apart of Haemophilus influenzae type b vaccine.
Study: NCT03440073

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulligan Concept Intervention
Description: The concept is a manual therapy paradigm that includes a clinician applying joint mobilizations and having the patient perform concurrent active, pain free, movement.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Mulligan Concept Treatment
Description: The treating clinician will ask the participant to perform the movements associated with the Mulligan Concept technique. The clinician will have her hands on the participant during the movement but will not apply any pressure or force.
Study: NCT03509818

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: plyometric exercise
Description: acute plyometric exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: acute aerobic exercise
Study: NCT03729986

Intervention type: OTHER
Intervention: Loaded inspiratory muscle test
Description: Loaded inspiratory muscle tests will be set at 30% of maximal inspiratory pressure in sitting and supine positions. The orders of the two loaded test conditions will be conducted in random order with at least 20 minute separation. This is an observational study. Subjects will perform only 15 breaths with each loaded test condition to exam the performance of their inspiratory muscles. Loaded inspiratory muscle test is not for training.
Study: NCT02996422

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School-based water campaign
Description: Includes: 1) the installation of filtered water bottle refilling stations, 2) the distribution of reusable water bottles to all students and teachers, and 3) a social marketing campaign to support the increase of water consumption among students.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community cooking classes
Description: Cooking classes will be delivered to groups of 8-12 adult participants as a series of 8 weekly classes in community venues. The content of each class is driven by topics and themes identified and prioritized by community members, namely cooking healthy on tight budget.
Study: NCT00641108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADAM SPECT plus Cognitive Therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADAM SPECT plus No Therapy
Study: NCT01998061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGFR tyrosine kinase inhibitor
Description: Arm A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGFR tyrosine kinase inhibitor with chemotherapy
Description: Arm B
Study: NCT02520492

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: noninvasive method of ICP measurements (Elios)
Study: NCT00606645

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XmAb2513
Description: Intravenous infusion of XmAb2513 administered at a dose of 0.3, 1.0, 3.0, 6.0, 9.0, or 12 mg/kg in sequential dose cohorts.
Study: NCT02491177

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: cMM
Description: Home visits from community mentor mothers

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: cMM
Description: Home visits from community mentor mothers

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Text Messaging
Description: Text messages received on mobile phone

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Text Messaging
Description: Text messages received on mobile phone
Study: NCT00152204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine used for IPTi
Description: Doses of IPTi with SP delivered alongside doses 2 \& 3 of DTP/HB vaccination and alongside measles vaccination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPTi
Description: Doses of IPTi with SP delivered alongside doses 2 \& 3 of DTP/HB vaccination and alongside measles vaccination
Study: NCT01776853

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Glucose

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fructose

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fructans
Study: NCT04620889

Intervention type: DEVICE
Intervention: AV Access
Description: Arteriovenous shunting for blood access.

Intervention type: DEVICE
Intervention: PVP
Description: Bypass or reconstruction of diseased or occluded blood vessels
Study: NCT01534481

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Donor Milk
Description: Donor milk provided by the Human Milk Banking Association of North America

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Preterm Formula
Description: Preterm Formula determined by center practice.
Study: NCT03886493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: dupilumab 600 mg SQ on day 1, and then 300 mg SQ on days 8,15, 22, 29, 36, 43.
Study: NCT02639247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL/VOX
Description: 400/100/100 mg FDC tablet administered orally once daily with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: 400/100 mg FDC tablet administered orally once daily without regard to food
Study: NCT00435630

Intervention type: OTHER
Group type: OTHER
Intervention: LapSim training
Description: complete curriculum training on LapSim surgical simulator
Study: NCT00484341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low-dose NGR-hTNF
Description: NGR-hTNF: 0.8 mcg/m² as 60-minutes intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low-dose NGR-hTNF
Description: NGR-hTNF: 0.8 mcg/m² as 60-minutes intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high-dose NGR-hTNF
Description: NGR-hTNF: 45 mcg/m² as 60-minutes intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high-dose NGR-hTNF
Description: NGR-hTNF: 45 mcg/m² as 60-minutes intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin: 60 mg/m² intravenous infusion over 15 minutes (starting 1 hour after the end of NGR-hTNF infusion) on day 1 every 3 weeks for a maximum of 6 cycles or until cumulative dose of 550 mg/m²

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin: 60 mg/m² intravenous infusion over 15 minutes (starting 1 hour after the end of NGR-hTNF infusion) on day 1 every 3 weeks for a maximum of 6 cycles or until cumulative dose of 550 mg/m²
Study: NCT02054975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D2 + vitamin D3
Description: higher dose vitamin D

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: lower dose vitamin D
Study: NCT03330444

Intervention type: PROCEDURE
Intervention: Endometrial biopsy and endometrial fluid collection
Description: On the same day that the EB for ERA is indicated, in day 5 of a HRT cycle with 5 days of progesterone, according to the common clinical practice, a sample of EF will be aspirated immediately prior to EB for ERA. This EF sample will be used for the non-invasive diagnosis of the microbiome, also a small portion of the endometrial tissue obtained for the endometrial receptivity diagnosis by ERA will be used as a control for the study of the endometrial microbiome. Those patients with a receptive endometrium will continue their ART according to the standard clinical protocol. Those patients with non-receptive endometrium will follow the recommendation derived of the ERA test for the election of the day for a second EB sample, in which the collection of EF sample will be repeated. Finally, the receptivity and microbiome results in EF will be correlated with that on the endometrial tissue, and with the reproductive outcomes of these patients after the embryo transfer.

Intervention type: PROCEDURE
Intervention: Endometrial biopsy and endometrial fluid collection
Description: On the same day that the EB for ERA is indicated, in day 5 of a HRT cycle with 5 days of progesterone, according to the common clinical practice, a sample of EF will be aspirated immediately prior to EB for ERA. This EF sample will be used for the non-invasive diagnosis of the microbiome, also a small portion of the endometrial tissue obtained for the endometrial receptivity diagnosis by ERA will be used as a control for the study of the endometrial microbiome. Those patients with a receptive endometrium will continue their ART according to the standard clinical protocol. Those patients with non-receptive endometrium will follow the recommendation derived of the ERA test for the election of the day for a second EB sample, in which the collection of EF sample will be repeated. Finally, the receptivity and microbiome results in EF will be correlated with that on the endometrial tissue, and with the reproductive outcomes of these patients after the embryo transfer.
Study: NCT02930707

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Description: ultrasound guided TAP block with 20 mL of 0.25% bupivacaine plus 2 mL magnesium sulfate 10% (200 mg), on each side of the abdominal wall.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine
Description: ultrasound guided TAP block with 20 mL of 0.25% bupivacaine on each side of the abdominal wall.
Study: NCT04176107

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Informative video
Description: Exposure to informative video before cesarean delivery
Study: NCT03763734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: An intravenous bolus dose of dexamethasone given prior to surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: An intravenous bolus dose of dexamethasone given prior to surgery.
Study: NCT05225519

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: long-sleeved white shirt impregnated with a long-infrared irradiation
Description: Usage of an experimental shirt for a period of 12 weeks.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: long-sleeved white shirt
Description: Usage of an experimental shirt for a period of 12 weeks.
Study: NCT03541278

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MIT
Description: periareolar intraparenchymal, high volume and ultrasonographic guidance

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IM-SLNB
Description: IM-SLNB was performed for IMLN visualized patients
Study: NCT01173510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir plus Truvada
Description: Raltegravir 400 mg twice daily plus tenofovir/emtricitabine (Truvada) one tablet once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atripla
Description: Efavirenz/Emtricitabine/Tenofovir DF one tablet once daily
Study: NCT02255929

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Gamma Knife Radiosurgery
Study: NCT00888914

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RT001
Description: RT001

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RT001
Description: RT001

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RT001
Description: RT001

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RT001
Description: RT001

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Comparator
Description: Vehicle Comparator
Study: NCT01336244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0778
Description: capsules containing 50 or 100 mg of GLPG0778

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: multiple dose, aqueous formulation, 13 days days, matching ascending dose schedule
Study: NCT04656405

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online real-time quality measurement and feedback video-based CPR training
Description: Participants in the online real-time quality measurement and feedback video-based CPR training program group will access an online training center with laptop computers provided by the researcher. All education and communication is conducted online. The study instructors shows the study participants an edited version of the CPR training video used in the conventional CPR training program. A Little Anne QCPR mannequin (Laerdal, Stavanger, Norway) and SkillGuide (Laerdal, Stavanger, Norway) are provided so that the participants can use while watching the video and during the following hands-on practice session.~After watching the video, hands-on practice will be conducted by the instructor on-line. The instructor will watch each individual participants CPR performance via video conferencing and collect real-time performance data using the QCPR mannequin device. Using this information, the instructor will provide real-time online feedback to participants.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Online real-time feedback video-based CPR training without quality measurement
Description: Participants in the online real-time feedback video-based CPR training without quality measurement program group will access an online training center with laptop computers provided by the researcher. All education and communication is conducted online. When study participants access the online training center, study instructors shows the study participants an edited version of the CPR training video used in the conventional CPR training program. A Little Anne QCPR mannequin (Laerdal, Stavanger, Norway) is provided so that the participants can use while watching the video and during the following hands-on practice session.~After watching the video, hands-on practice will be conducted by the instructor on-line. The instructor will watch each individual participants CPR performance via video conferencing. The instructor will provide real-time online feedback to participants.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional CPR training
Description: Participants in the conventional CPR training program group will be provided CPR education with the Home Education and Resuscitation Outcome Study (HEROS) program that is currently provided in Seoul, Korea. The HEROS program is a 1-hour training course, consisting of a 30-minute video-based self-instruction training with a mannequin. The program also includes a bystander CPR simulation with a simulated dispatcher using the participants own cell phone. Little Anne QCPR mannequin (Laerdal, Stavanger, Norway) and SkillGuide (Laerdal, Stavanger, Norway) device are provided to measure and give feedback on the participants CPR performance.
Study: NCT03428997

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lotion
Description: Formulated Lotion F# 13451-131 was applied on an occlusive patch and placed on a test site on each subjects back three times a week for four weeks.

Intervention type: OTHER
Group type: OTHER
Intervention: Negative Control
Description: Control. An undosed occlusive patch was placed on a test site on each subjects back three times a week for four weeks.
Study: NCT03368625

Intervention type: RADIATION
Group type: OTHER
Intervention: Stereotactic Radiosurgery
Description: Stereotactic Radiosurgery before surgical resection of brain mets.
Study: NCT02424812

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifebuoy School of Five Handwashing Intervention
Study: NCT01947959

Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, Bay59-7939)
Description: The treatment of DVT or PE, and prevention of recurrent DVT and PE in adult patients (15 mg rivaroxaban twice daily \[bid\] for 3 weeks, then 15 mg or 20 mg once daily \[od\], tablets).~The prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (stroke prevention in atrial fibrillation \[SPAF\]) with one or more risk factors (20 mg rivaroxaban \[od\], tablets).~The prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery (recommended dose: 10 mg rivaroxaban \[od\] tablets for 35 days following hip replacement surgery and 14 days following knee replacement surgery).~Co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers (recommended dose 2.5 mg rivaroxaban tablets \[bid\]).

Intervention type: DRUG
Intervention: Standard of care
Description: For DVT/PE treatment and SPAF, standard of care is treatment with the most widely used vitamin K antagonist, phenprocoumon, and for the secondary prevention of ACS, standard of care is antiplatelet drug(s) such as low-dose acetylsalicylic acid, clopidogrel, dipyridamole, prasugrel, ticlopidine and ticagrelor.
Study: NCT03893981

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioception and Balance Program
Description: Balance Trainer device and playing ball in tandem position for using to improve balance, vibration and reposition exercises for using to improve proprioception. Progressive of training will increase after each 2 weeks.Patients will be taken to the treatment program 3 days in a week for 8 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthening Program
Description: Exercises which include open and closed kinetic chain exercise will be applied to strength knee and hip muscle. Progressive of training will increase after each 2 weeks. Patients will be taken to the treatment program 3 days in a week for 8 weeks.
Study: NCT02892825

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: headphones with music

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Music
Description: headphones without music
Study: NCT03329599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polycap
Description: Assigned to a polypill containing 2/3 antihypertensives, a moderate/high-intensity statin and Aspirin to be taken orally, once daily in the form of a hard capsule
Study: NCT01459666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dysport (abobotulinumtoxinA)
Description: Intramuscular injection effects lasting up to 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bacteriostatic 0.9% Sodium Chloride (vehicle)
Description: Intramuscular injection
Study: NCT01061385

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReShape Intragastric Balloon
Description: Placement of ReShape Medical Intragastric Balloon for twenty four weeks

Intervention type: OTHER
Group type: OTHER
Intervention: Control Arm
Description: Behavioral Modification (Diet and exercise counseling) alone
Study: NCT03586271

Intervention type: PROCEDURE
Intervention: trifocal lens
Description: phacoemusification + trifocal lens(AT Lisa tri 839MP) implantation

Intervention type: PROCEDURE
Intervention: trifocal lens
Description: phacoemusification + trifocal lens(AT Lisa tri 839MP) implantation

Intervention type: PROCEDURE
Intervention: trifocal lens
Description: phacoemusification + trifocal lens(AT Lisa tri 839MP) implantation
Study: NCT03771404

Intervention type: OTHER
Group type: OTHER
Intervention: blood sampling
Description: Patients' peripheral blood will be obtained before the surgical excision of the primary tumor as well as 1-month post-op and every 3-6 months thereafter until disease progression and upon disease relapse for the evaluation of ctDNA and CTCs. Different sites of the primary tumor as well as the regional involved lymph nodes and, in selected patients, biopsies from metastatic sites will be genotyped by NGS as well.
Study: NCT03586271

Intervention type: PROCEDURE
Intervention: bifocal lens 1
Description: phacoemusification +bifocal lens(Diff-aay) implantation

Intervention type: PROCEDURE
Intervention: bifocal lens 1
Description: phacoemusification +bifocal lens(Diff-aay) implantation

Intervention type: PROCEDURE
Intervention: bifocal lens 1
Description: phacoemusification +bifocal lens(Diff-aay) implantation

Intervention type: PROCEDURE
Intervention: bifocal lens 2
Description: phacoemusification +bifocal lens (ReSTOR +3.0D) implantation

Intervention type: PROCEDURE
Intervention: bifocal lens 2
Description: phacoemusification +bifocal lens (ReSTOR +3.0D) implantation

Intervention type: PROCEDURE
Intervention: bifocal lens 2
Description: phacoemusification +bifocal lens (ReSTOR +3.0D) implantation

Intervention type: PROCEDURE
Intervention: bifocal lens 3
Description: phacoemusification +bifocal lens (ReSTOR +2.5D) implantation

Intervention type: PROCEDURE
Intervention: bifocal lens 3
Description: phacoemusification +bifocal lens (ReSTOR +2.5D) implantation

Intervention type: PROCEDURE
Intervention: bifocal lens 3
Description: phacoemusification +bifocal lens (ReSTOR +2.5D) implantation
Study: NCT03018808

Intervention type: OTHER
Intervention: CAT
Description: The CAT is a questionnaire for COPD patients and is designed to measure the impact of COPD on a person's life over time.

Intervention type: OTHER
Intervention: CAT
Description: The CAT is a questionnaire for COPD patients and is designed to measure the impact of COPD on a person's life over time.

Intervention type: OTHER
Intervention: CAT
Description: The CAT is a questionnaire for COPD patients and is designed to measure the impact of COPD on a person's life over time.